Weekly Research Analysts’ Ratings Changes for Hinge Health (HNGE)

Several brokerages have updated their recommendations and price targets on shares of Hinge Health (NYSE: HNGE) in the last few weeks:

• 1/9/2026 – Hinge Health had its price target lowered by analysts at Piper Sandler from $71.00 to $60.00. They now have an “overweight” rating on the stock.
• 1/8/2026 – Hinge Health is now covered by analysts at Wells Fargo & Company. They set an “overweight” rating and a $68.00 price target on the stock.
• 1/8/2026 – Hinge Health had its price target lowered by analysts at KeyCorp from $72.00 to $70.00. They now have an “overweight” rating on the stock.
• 1/8/2026 – Hinge Health is now covered by analysts at Wells Fargo & Company. They set an “overweight” rating and a $68.00 price target on the stock.
• 1/6/2026 – Hinge Health had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $59.00 price target on the stock.
• 1/5/2026 – Hinge Health had its price target lowered by analysts at Barclays PLC from $65.00 to $60.00. They now have an “overweight” rating on the stock.
• 12/28/2025 – Hinge Health was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
• 12/20/2025 – Hinge Health was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 12/6/2025 – Hinge Health was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.

Insider Activity at Hinge Health

In related news, major shareholder Insight Holdings Group, Llc sold 1,654,440 shares of the firm’s stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $47.76, for a total transaction of $79,016,054.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Kristina M. Leslie sold 1,250 shares of the firm’s stock in a transaction dated Friday, November 21st. The shares were sold at an average price of $45.68, for a total value of $57,100.00. Following the completion of the sale, the director owned 27,750 shares of the company’s stock, valued at approximately $1,267,620. This represents a 4.31% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 2,805,105 shares of company stock valued at $128,216,614.

Hinge Health (NYSE: HNGE) is a digital musculoskeletal (MSK) clinic that provides end-to-end solutions for the prevention and management of musculoskeletal conditions. The company’s platform combines wearable motion sensors, personalized exercise therapy guided by licensed physical therapists, and behavioral health coaching to deliver tailored treatment plans. By integrating technology with evidence-based clinical protocols, Hinge Health aims to reduce pain, improve mobility and decrease reliance on more invasive interventions such as surgery or opioid prescriptions.

Founded in 2015 and headquartered in San Francisco, Hinge Health partners with employers, health plans and other payers to offer its self-directed, app-based programs.